We are live on ! Find out more
INSY

Insys Therapeutics, Inc.
INSY

Delisted

INSY was delisted on the 18th of June, 2019.

133 hedge funds and large institutions have $841M invested in Insys Therapeutics, Inc. in 2015 Q1 according to their latest regulatory filings, with 34 funds opening new positions, 44 increasing their positions, 42 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

143% more first-time investments, than exits

New positions opened: 34 | Existing positions closed: 14

44% more capital invested

Capital invested by funds: $585M → $841M (+$256M)

34% more call options, than puts

Call options by funds: $7.25M | Put options by funds: $5.39M

18% more funds holding

Funds holding: 113133 (+20)

5% more repeat investments, than reductions

Existing positions increased: 44 | Existing positions reduced: 42

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

Holders
133
Holders Change
+20
Holders Change %
+17.7%
% of All Funds
3.54%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.05%
New
34
Increased
44
Reduced
42
Closed
14
Calls
$7.25M
Puts
$5.39M
Net Calls
+$1.86M
Net Calls Change
-$2.53M
Name Holding Trade Value Shares
Change
Change in
Stake
PAM
101
Panagora Asset Management
Massachusetts
$337K +$155K +5,846 +101%
BA
102
BlackRock Advisors
Delaware
$324K +$37.4K +1,414 +15%
TI
103
Trexquant Investment
Connecticut
$319K -$402K -15,200 -58%
VOYA Investment Management
104
VOYA Investment Management
Georgia
$309K
Bank of America
105
Bank of America
North Carolina
$277K -$6.08K -230 -2%
Tudor Investment Corp
106
Tudor Investment Corp
Connecticut
$266K -$417K -15,756 -63%
MCTIC
107
MacGuire Cheswick & Tuttle Investment Counsel
Connecticut
$238K +$217K +8,190 New
PCM
108
Price Capital Management
Louisiana
$237K +$216K +8,162 New
Jane Street
109
Jane Street
New York
$224K -$186K -7,026 -48%
CA
110
Commerzbank Aktiengesellschaft
Germany
$211K +$192K +7,274 New
BG
111
BlackRock Group
United Kingdom
$189K +$61K +2,308 +55%
Legal & General Group
112
Legal & General Group
United Kingdom
$106K
TWA
113
TCI Wealth Advisors
Arizona
$102K +$70.7K +2,672 +323%
Canada Life
114
Canada Life
Manitoba, Canada
$102K +$84.6K +3,200 +958%
CLOS
115
Compagnie Lombard Odier SCmA
Switzerland
$58K +$52.9K +2,000 New
LTFS
116
Ladenburg Thalmann Financial Services
Florida
$57K +$5.87K +222 +13%
TRCT
117
Tower Research Capital (TRC)
New York
$52K +$37.1K +1,404 +351%
PCM
118
Prelude Capital Management
New York
$47K -$138K -5,200 -76%
Barclays
119
Barclays
United Kingdom
$43K -$50.9K -1,926 -56%
Creative Planning
120
Creative Planning
Kansas
$38K +$13.3K +504 +63%
MOACM
121
Mutual of America Capital Management
New York
$37K
Teacher Retirement System of Texas
122
Teacher Retirement System of Texas
Texas
$22K +$106 +4 +0.5%
BlackRock
123
BlackRock
New York
$14K
BNP Paribas Financial Markets
124
BNP Paribas Financial Markets
France
$13.9K +$12.6K +478 New
CB
125
Community Bank
New York
$12K +$10.6K +400 New

INSY Hedge Fund Activity: Q1 2015 in Review

133 of the 3,752 institutional investors tracked by Wall St. Rank reported a position in Insys Therapeutics, Inc. (INSY) for Q1 2015, worth a combined $841M — up 44% from $585M a quarter earlier.

Buyers outnumbered sellers: 34 funds opened new INSY positions and 14 closed out — a net gain of 20 holders — while 44 added to existing stakes and 42 trimmed.

The largest buyer was State Street, adding an estimated $20.3M. The largest seller was Point72 Asset Management, cutting an estimated $30.2M.

  • 133 institutional investors held Insys Therapeutics, Inc. (INSY) as of Q1 2015, up from 113 in Q4 2014.
  • Funds reported $841M of Insys Therapeutics, Inc. stock for Q1 2015, up 44% quarter-over-quarter.
  • 34 funds opened new Insys Therapeutics, Inc. positions in Q1 2015 and 14 closed out, a net change of +20 holders.
  • The largest Insys Therapeutics, Inc. buyer in Q1 2015 was State Street, an estimated $20.3M added.
  • The largest Insys Therapeutics, Inc. seller in Q1 2015 was Point72 Asset Management, an estimated $30.2M sold.

Based on aggregated 13F filings for Q1 2015.